Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, multi-centre, single-arm, open-label, dose-escalation study that will
evaluate the safety and efficacy of IV GSK2857916 in combination with PO pomalidomide and
low-dose PO dexamethasone in subjects with relapsed and/or refractory MM.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Canadian Myeloma Research Group Myeloma Canada Research Network